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1. Introduction 
Pluripotent stem cells have the ability to differentiate into cells of the three primary germ 
layer lineages, ectoderm, mesoderm and endoderm. The most studied type of pluripotent 
stem cells are embryonic stem cells (ESC), cells derived from the inner cell mass of embryos 
at the blastocyst stage of development (Evans and Kaufman, 1981; Martin, 1981; Thomson et 
al., 1998). The pluripotent property of human embryonic stem cells (hESC) makes them 
useful for the development of cellular therapies to replace diseased or degenerated cells in 
the body. Moreover, hESC also possess the ability to propagate indefinitely in vitro while 
maintaining a normal karyotype, and thus can provide an unlimited source of cells for the 
development of cell replacement therapies (Pera et al., 2000). However, one of the major 
hurdles in hESC research has been the ethical implications of using stem cells derived from 
embryos. Furthermore, generation of patient-specific stem cell lines may overcome some of 
the issues associated with immuno-compatibility in cell replacement therapy.  
The breakthrough studies conducted by Shinya Yamanaka’s group demonstrated direct 
reprogramming of mouse or human fibroblasts back to pluripotent cells, creating so-called 
induced pluripotent stem cells (iPSC) (Takahashi et al., 2007; Takahashi and Yamanaka, 
2006). Studies of iPSC revolutionized stem cell research by creating a more reproducible 
method to generate sufficient amounts of patient-specific pluripotent cells and bypassing 
the ethical implications surrounding research utilizing human embryos. iPSC also provide 
an alternative approach to generate disease-specific lines for mechanistic studies in disease 
modeling, as well as high throughput screening for drug discovery or toxicology studies 
(Amabile and Meissner, 2009). As the area of iPSC research is rapidly evolving, this review 
aims to summarize and discuss the current techniques used for the generation of iPSC.  
2. Reprogramming factors used in generation of induced pluripotent stem 
cells (iPSC) 
The initial derivation of iPSC by Shinya Yamanaka’s group was achieved by overexpressing 
four transcription factors first in mouse and then human fibroblasts, namely Octamer-
binding transcription factor 4 (Oct4), Sex-determining region Y HMG box 2 (Sox2), Krüppel-
like factor 4 (Klf4) and v-myc myelocytomatosis viral oncogene homolog (c-Myc), often 
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referred to as the ‘Yamanaka factors’ (Takahashi et al., 2007; Takahashi and Yamanaka, 
2006). Alternatively, a study from James Thomson’s lab identified a different combination of 
factors for the generation of human iPSC, using Oct4, Sox2, Nanog and Lin28 (Yu et al., 
2007). Subsequent reports from many labs have contributed to a growing list of 
reprogramming factors used for iPSC generation, including Estrogen-related receptor beta 
(Esrrb), Sal-like 4 (Sall4), microRNAs (miRNA), simian virus 40 large-T (SV40LT) antigen 
and human telomerase reverse transcriptase (hTERT). This section will provide a 
background of our understanding of these reprogramming factors in regulating the cell fate 
of pluripotent stem cells and discuss their role during direct somatic cell reprogramming. 
Other strategies to enhance reprogramming efficiency will also be discussed, such as 
supplementation with small molecules as well as knockdown of p53, p21 and p16.  
2.1 Oct4 
Oct4 was one of the first transcription factors identified to be a master regulator of cellular 
pluripotency (Okamoto et al., 1990; Rosner et al., 1990; Scholer et al., 1989). During mouse 
development in vivo, Oct4 expression is restricted to the inner cell mass, primitive ectoderm 
and primordial germ cells (Pesce and Scholer, 2001). Similarly in vitro, ESC and embryonal 
carcinoma cells (ECC) have high expression of Oct4, which is reduced upon their 
differentiation (Assou et al., 2007; Rosner et al., 1990).  
Although expression of Oct4 is fundamental for the maintenance of pluripotency and 
development of the inner cell mass in mice (Nichols et al., 1998), complex regulation of its 
precise level is required to prevent cells from differentiating into other lineages. A transient 
increase in endogenous Oct4 levels has been observed upon mesodermal differentiation of 
mouse embryonic stem cells (mESC) (Zeineddine et al., 2006). Furthermore in various over-
expression studies, an increase in Oct4 expression can cause mESC to differentiate into 
endoderm, mesoderm and neuroectoderm lineages (Niwa et al., 2000; Shimozaki et al., 2003; 
Zeineddine et al., 2006). On the other hand, repression of Oct4 levels results in a loss of 
pluripotency and promotes trophectodermal differentiation in mESC and hESC (Matin et al., 
2004; Niwa et al., 2000). Consistent with these studies, Oct4 has been shown to directly 
inhibit the expression of major trophectoderm differentiation regulators such as caudal type 
homeobox 2 (Cdx2) and Eomesdermin (Eomes) (Liu et al., 1997; Liu and Roberts, 1996; Niwa 
et al., 2005). Together these studies highlight the significance of the critical range of Oct4 
level required to maintain ESC pluripotency (Niwa et al., 2000).  
As a master regulator of pluripotency, Oct4 was one of the original four factors utilized by 
Yamanaka and colleagues in the generation of iPSC in both mouse and human (Takahashi et 
al., 2007; Takahashi and Yamanaka, 2006). As seen in Oct4 over-expression and down-
regulation experiments in ESC, the precise level of Oct4 in combination with other 
reprogramming factors is also essential for efficient generation of iPSC (Papapetrou et al., 
2009). Using bicistronic vectors, Papapetrou et al. (2009) showed that a 3-fold higher 
expression of Oct4 compared to Sox2, Klf4 and c-Myc enhanced iPSC generation 
(Papapetrou et al., 2009). Interestingly, overexpression of Oct4 alone was sufficient to induce 
reprogramming in neural stem cells that already express high endogenous level of Sox2, c-
Myc and Klf4  (Kim et al., 2009b; Kim et al., 2009c). To date, most protocols for generation of 
iPSC require ectopic expression of Oct4, underlying the important role of Oct4 during direct 
somatic cell reprogramming (Feng et al., 2009b). Recently, Heng et al. (2010) demonstrated 
that an orphan nuclear receptor Nr5a2 can functionally replace Oct4 in the generation of 
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mouse iPSC (Heng et al., 2010). However, the precise role of Nr5a2 in regulating cell fate in 
pluripotent stem cells remains unclear. Further research is also needed to confirm the ability 
of Nr5a2 to replace Oct4 in human iPSC generation. 
2.2 Sox2 
Sox2 is an important transcription factor in pluripotent stem cells as well as precursor cells 
of the neural compartment. It is expressed in the inner cell mass, epiblast and 
extraembryonic ectodermal cells during mouse embryo development (Avilion et al., 2003; 
Miyagi et al., 2004). Unlike Oct4, Sox2 expression is maintained in neural stem cells (Ellis et 
al., 2004; Graham et al., 2003) and over-expression of Sox2 favors neural differentiation in 
mESC (Kopp et al., 2008; Zhao et al., 2004). Sox2 is known to interact with several binding 
partners, including Oct4 in the maintenance of pluripotency (Yuan et al., 1995). In a genome-
wide chromatin immunoprecipitation study in hESC, Sox2 and Oct4 were found to share 
many target genes, many of which are transcription factors important in development 
(Boyer et al., 2005).  
Importantly, Sox2 was shown to be indispensable for maintaining pluripotency. Sox2 
knockout mouse embryos are unable to form an epiblast and fail to develop past the 
implantation stage (Avilion et al., 2003). Down-regulation of Sox2 in mESC and hESC results 
in loss of pluripotency and differentiation towards the trophectoderm cell lineage (Adachi et 
al., 2010; Fong et al., 2008; Li et al., 2007; Masui et al., 2007). Somewhat surprising was the 
finding that expression of many Sox2 target genes were not affected by the loss of Sox2 
(Masui et al., 2007). The authors in this study suggested potential compensation of Sox2 
function by other members of the Sox family. Consistent with this idea, Nakagawa et al. 
(2008) demonstrated that Sox1, Sox3, Sox15 and Sox18 have the ability to replace Sox2 to 
some extent in iPSC generation (Nakagawa et al., 2008). To date, Sox2 and Oct4 remain to be 
the two fundamental reprogramming factors and are widely used in various protocols to 
generate iPSC. Similar to Oct4, it should be noted that ectopic expression of Sox2 can be 
omitted in the generation of iPSC, if the starting cell type expresses substantial levels of Sox2  
(Utikal et al., 2009a). 
2.3 Nanog 
Nanog is a homeodomain protein that is widely considered as a master regulator for stem 
cell pluripotency (Chambers et al., 2003; Mitsui et al., 2003). Nanog expression is restricted 
to the inner cell mass, epiblast and primordial germ cells in the early embryo, as well as a 
number of pluripotent cells lines such as ESC, ECC and embryonic germ cells (Chambers et 
al., 2003). During embryo development, Nanog plays a role in suppressing Cdx2, a master 
regulator of trophectoderm differentiation, and in turn suppression of Cdx2 specifies the 
inner cell mass fate (Chen et al., 2009). Moreover, Nanog can also physically interact with 
Oct4 (Wang et al., 2006) and cooperates extensively with Oct4 and Sox2 to form an 
autoregulated core-transcriptional network that maintain stem cell pluripotency (Boyer et 
al., 2005; Chen et al., 2008; Kim et al., 2008).  
Unlike Oct4 or Sox2, sustained expression of Nanog renders mESC and hESC resistant to 
differentiation (Chambers et al., 2003; Darr et al., 2006; Ivanova et al., 2006). However in the 
absence of Oct4, Nanog alone is not sufficient to maintain mESC self-renewal, suggesting 
that Nanog plays a subservient role in maintaining self-renewal (Chambers et al., 2003). This 
is also supported by evidence from Nanog knockdown studies. Although early studies 
www.intechopen.com
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
376 
suggested that a reduction of Nanog resulted in differentiation of mESC and hESC (Fong et 
al., 2008; Hyslop et al., 2005; Ivanova et al., 2006; Mitsui et al., 2003), it was later discovered 
that transient down-regulation of Nanog can be reversible and does not necessarily mark 
commitment to differentiation (Chambers et al., 2007). In this respect, mESC can remain 
undifferentiated in the absence of Nanog, but are more prone to differentiation (Chambers 
et al., 2007). 
Given the important role of Nanog in establishing cell pluripotency, it was somewhat 
surprising that the initial derivation of iPSC could be achieved without the ectopic 
expression of Nanog (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). However, 
Nanog has proved to be a valuable marker for identification of fully reprogrammed iPSC 
that are germline competent (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). 
Furthermore, ectopic expression of Nanog in combination with Oct4, Sox2, Klf4 and c-Myc 
seems to accelerate the reprogramming kinetics of somatic cells to iPSC, but has no effect on 
the overall reprogramming efficiency (Hanna et al., 2009).  
2.4 Klf4 
Klf4 and its family members have emerged as important regulators for maintaining 
pluripotency. Klf4 belongs to the Krüppel-like factor (Klf) family of zinc finger transcription 
factors. Klf4 can act as an oncogene or a tumor suppressor gene depending on the 
physiological context (McConnell et al., 2007; Rowland and Peeper, 2006). Klf4 is usually 
expressed in adult tissues that possess some degree of regenerative capability, including 
intestine, gut, skin and testis (Nandan and Yang, 2009). Li et al. (2005) provided the first 
evidence that Klf4 plays a role in regulating stem cell pluripotency, by showing that 
overexpression of Klf4 prevents differentiation of mESC into erythroid progenitors (Li et al., 
2005). In conjunction with Oct4, Sox2 and c-Myc, Klf4 was among the first factors to be used 
to generate iPSC (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). However, the 
current view is that Klf4 acts only as a secondary factor to enhance somatic cell 
reprogramming, as iPSC can be generated without Klf4 using a different combination of 
reprogramming factors (Yu et al., 2007). Klf4 was later discovered to be an important 
component of the core transcriptional network that regulates expression of Oct4, Sox2, 
Nanog, Myc and also Klf4 itself (Chen et al., 2008; Kim et al., 2008). Furthermore, Klf4 can 
directly interact and cooperate with Oct4 and Sox2 to activate a subset of ESC specific genes, 
including Nanog and Lefty1 (Nakatake et al., 2006; Wei et al., 2009). Klf4 also acts to inhibit 
apoptosis by suppressing p53 (Rowland et al., 2005), which helps to reprogram somatic cells 
to a pluripotent state (See discussion below).  
Importantly, other Klf family members including Klf1, Klf2 or Klf5, can substitute for Klf4 in 
iPSC generation (Nakagawa et al., 2008), which suggests that functional redundancies exist 
among the Klf family members in establishing cell pluripotency. This also explains the 
observation that Klf4 knockdown in mESC exhibited no obvious phenotype (Jiang et al., 
2008; Nakatake et al., 2006), whereas triple knockdown of Klf2, Klf4 and Klf5 resulted in 
rapid differentiation of mESC (Jiang et al., 2008). However, isoform-specific functions of Klf4 
and Klf5 are also observed. Previous studies showed that Klf5 knockout mice result in 
embryo lethality and defects in implantation (Ema et al., 2008), whereas Klf4 knockout mice 
are normal during early embryo development but die soon after birth due to loss of skin 
barrier function (Segre et al., 1999). Furthermore, Ema et al. (2008) demonstrated that 
knocking out Klf5 in mESC results in spontaneous differentiation. Although introduction of 
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Klf4 can rescue the spontaneous differentiation phenotype, proliferation is significantly 
decreased (Ema et al., 2008). Further studies are needed to dissect the precise roles of 
different Klf members in regulating cell pluripotency.  
2.5 Lin28 
Lin28 encodes for a cytoplasmic RNA binding protein that acts as a translational enhancer 
(Polesskaya et al., 2007). It was first identified as a heterochronic gene that regulates the 
developmental timing pathway in Caenorhabditis elegans (Moss et al., 1997). A previous 
transcriptome study has shown that Lin28 is a hESC-specific gene, suggesting that it may 
play a role in regulating stem cell pluripotency (Richards et al., 2004). However, functional 
studies of Lin28 in hESC and mESC yielded opposing results. In mESC, Lin28 knockdown 
resulted in decreased cell proliferation while overexpression of Lin28 enhanced cell 
proliferation (Xu et al., 2009a). In sharp contrast, Lin28 knockdown in hESC had no obvious 
phenotype, whereas Lin28 overexpression reduced proliferation and promoted 
extraembryonic endoderm differentiation (Darr and Benvenisty, 2009). Further studies are 
clearly needed to elucidate whether Lin28 has a different role in maintenance of pluripotent 
stem cells in mice and humans.  
Lin28 was first used in combination with Nanog, Oct4 and Sox2 to generate human iPSC, 
acting as an enhancer for somatic cell reprogramming much like Klf4 (Yu et al., 2007). 
However, it remains unclear how Lin28 contributes to induction of pluripotency. It was 
demonstrated that Lin28 can block the processing of let7 microRNA family members, a 
group of pro-differentiation microRNA that also act as tumor suppressors (Melton et al., 
2010; Viswanathan et al., 2008). Members of the let7 microRNA family have been shown to 
repress expression of oncogenes such as c-Myc and Ras. Hence, down-regulation of let7 by 
Lin28 could increase cell proliferation and drive cellular transformation (Viswanathan et al., 
2009). Consistent with this idea, a recent study in mice demonstrated that Lin28 accelerates 
reprogramming kinetics by enhancing cell proliferation (Hanna et al., 2009). Another 
proposed mechanism of Lin28 action is that it can selectively regulate gene expression at a 
post-transcriptional level, enhancing translation of anti-differentiation mRNAs while 
degrading pro-differentiation mRNAs to maintain pluripotency. A previous study 
demonstrated that Lin28 can reside in polysomal ribosome fractions, in which mRNAs are 
translated (Balzer and Moss, 2007). Indeed, Lin28 has been shown to bind directly to Oct4 
mRNA in hESC to facilitate translation via interaction with RNA helicase A (Qiu et al., 
2010). Lin28 can also reside in P-bodies, in which mRNAs are degraded (Balzer and Moss, 
2007). Therefore, it remains speculative that Lin28 may be able to selectively degrade certain 
pro-differentiation mRNA to support stem cell pluripotency. Further studies are needed to 
confirm this hypothesis.  
2.6 c-Myc 
The basic helix–loop–helix/leucine zipper transcription factor c-Myc has a well documented 
role in cellular transformation and tumor progression, by controlling cell cycle, apoptosis, 
protein biosynthesis and metabolism (Kendall et al., 2006; Patel et al., 2004). c-Myc has been 
shown to regulate its target genes through interactions with the transcription machinery, as 
well as exerting epigenetic regulation via interactions with chromatin remodeling 
complexes, DNA methyltransferases and histone modifying enzymes (Eilers and Eisenman, 
2008). Subsequent studies also identified a critical role of c-Myc in mESC maintenance. 
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Overexpression of c-Myc enables mESC to be resistant to differentiation, whereas expression 
of a dominant negative form of c-Myc promotes differentiation (Cartwright et al., 2005). 
However, a functional study of c-Myc in hESC yielded rather different results. 
Overexpression of c-Myc drives hESC to apoptosis and differentiation into extraembryonic 
endoderm and trophectoderm (Sumi et al., 2007).  
c-Myc was identified as one of the four ‘Yamanaka factors’ initially used to generate both 
mouse and human iPSC (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). Other 
reports have also shown that c-Myc can be substituted by two other related family members, 
N-Myc and L-Myc, during somatic cell reprogramming (Blelloch et al., 2007; Nakagawa et 
al., 2008). Subsequent studies demonstrated that somatic cell reprogramming can be 
achieved without c-Myc, albeit with significantly reduced efficiency and slower kinetics 
(Nakagawa et al., 2008; Wernig et al., 2008). Furthermore, reactivation of c-Myc has been 
observed in iPSC following blastocyst incorporation, resulting in tumor formation in the 
chimeric mice (Okita et al., 2007). This finding raises concerns about the safety of using iPSC 
generated with c-Myc for clinical applications. Understanding the molecular mechanism of 
c-Myc contributions during somatic cell reprogramming may help identify alternative 
enhancers for iPSC generation that are less tumorigenic.  
Recent studies have shed light on the function of c-Myc during somatic cell reprogramming. 
Genome-wide analysis of promoter binding demonstrated that c-Myc regulates a different 
set of target genes compared to other pluripotency factors Oct4, Sox2 and Klf4 in mESC and 
iPSC (Chen et al., 2008; Kim et al., 2008; Sridharan et al., 2009). This suggests that c-Myc may 
have a very different function than the other transcription factors associated with induction 
of pluripotency. One proposed function is that c-Myc acts to repress expression of somatic 
genes during the early reprogramming stage, a process that is necessary before the 
activation of pluripotency gene networks (Sridharan et al., 2009). Another proposed 
mechanism of action of c-Myc is that it may induce a cell cycle program that is necessary for 
self-renewal of stem cells, activating genes which promote proliferation (i.e. cyclin A, cyclin 
E or E2F) and repressing genes associated with growth arrest (i.e. p21, p27) (Vermeulen et 
al., 2003). Finally, c-Myc may exert epigenetic control by modifying the chromatin structure 
to become suitable for activation of the self-renewal gene program, thus allowing somatic 
cells to revert back to a pluripotent state (Knoepfler et al., 2006).  
2.7 Esrrb 
Esrrb belongs to a subfamily of orphan nuclear receptors that are closely related to estrogen 
receptors  (Giguere, 2002). The natural ligands for Esrrb are currently unknown. 
Nevertheless, Esrrb and its family members can bind to DNA and function as 
transcriptional activators without exogenous ligands (Giguere, 2002). Most of our 
knowledge of the role of Esrrb in regulating self-renewal comes from studies in mice. 
Overexpression of Esrrb is sufficient to maintain self-renewal of mESC in conditions that 
favour differentiation, possibly by maintaining the level of Oct4 expression (Zhang et al., 
2008). Also, knockdown of Esrrb level in mESC induces differentiation (Ivanova et al., 2006; 
Loh et al., 2006). These results identify Esrrb as a positive regulator of ESC pluripotency.  
Indeed, Esrrb has been used as a factor to reprogram somatic cells back to a pluripotent 
state. In the presence of Oct4 and Sox2, Feng et al. (2009) demonstrated that Esrrb could 
replace Klf4 as an enhancer to reprogram mouse fibroblasts into iPSC, albeit with lower 
reprogramming efficiency (Feng et al., 2009a). Furthermore, another family member Esrrg 
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also possesses a similar reprogramming ability when used in conjunction with Oct4 and 
Sox2 (Feng et al., 2009a). Genome-wide analysis of promoter binding suggested that Essrb 
shares many target genes with Oct4 and Sox2. Further studies demonstrated that Esrrb is a 
binding partner for Oct4 and Nanog in mESC (van den Berg et al., 2010; Wang et al., 2006), 
but whether it physically interacts with Sox2 remains to be determined. In summary, Esrrb 
was found to have a partially overlapping role with Klf4 in enhancing somatic cell 
reprogramming in mice, by cooperating with other pluripotency factors Oct4 and Nanog. To 
date, it has not yet been determined whether Esrrb plays a similar role in human cells.  
2.8 Sall4 
Sall4 belongs to the family of Spalt transcription factors that are characterized by highly 
conservative C2H2 zinc-finger domains (Sweetman and Munsterberg, 2006). Mutations of 
Sall4 in humans results in Okihiro syndrome, a disease characterized by limb deformities 
and eye movement deficits (Kohlhase et al., 2002). Sall4 is highly enriched in ESC, and is one 
of the ‘embryonic cell associated transcripts’ identified by Shinya Yamanaka’s group. A 
previous study indicated that knockdown of Sall4 promoted mESC differentiation, most 
notably into the trophectoderm lineage (Zhang et al., 2006). However, follow-up reports 
showed that Sall4-null mESC are able to remain pluripotent, albeit with impaired 
proliferation (Tsubooka et al., 2009; Yuri et al., 2009). A study by Yuri et al. (2009) also 
demonstrated high expression of trophectoderm markers in Sall4-null mESC (Yuri et al., 
2009). These results suggest that Sall4 is not essential to maintain pluripotency in mESC, but 
rather functions to stabilize the stem cell phenotype by promoting proliferation and possibly 
repressing trophectoderm differentiation. Furthermore, it is becoming clear that Sall4 is an 
integral part of the autoregulatory transcriptional network of Oct4, Sox2 and Nanog in 
mESC (Lim et al., 2008; Yang et al., 2008). These results suggest Sall4 is a possible candidate 
reprogramming factor for induced pluripotency.  
Recently, Wong et al. (2008) discovered that Sall4 can enhance the efficiency of 
reprogramming mouse fibroblasts through fusion with mESC (Wong et al., 2008). Sall4 also 
increases the reprogramming efficiency of mouse fibroblasts when used in combination with 
Oct4, Sox2 and Klf4 (Tsubooka et al., 2009). However, this enhancing effect of Sall4 in 
reprogramming is inconsistent in different human fibroblast cell types, possibly due to 
variations in endogenous levels of Sall4 in different samples (Tsubooka et al., 2009). Further 
studies of Sall4 in human pluripotent stem cells will clarify whether the role of Sall4 in 
regulating cell pluripotency is conserved between mouse and human.  
2.9 miRNA 
miRNA are small RNAs that provide post-transcriptional control of gene regulation. Once 
transcribed, primary miRNA undergo multiple processing steps to become mature miRNA 
that promote degradation or repress translation of target mRNA (Siomi and Siomi, 2010). A 
previous report provided evidence that miRNA play an important role in the inter-
connected transcriptional network regulated by pluripotency factors Oct4, Sox2 and Nanog 
in mESC (Marson et al., 2008). The pluripotency factors Oct4, Sox2 and Nanog are able to 
bind and regulate expression of specific miRNA, activating ESC specific miRNA while 
repressing those associated with differentiation (Barroso-delJesus et al., 2008; Marson et al., 
2008). It is believed that miRNA serve as a mechanism for Oct4, Sox2 and Nanog to fine-
tune the expression level of their target genes.  
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Recently, Robert Blelloch’s group described a subset of miRNA that play an important role 
in regulating the cell cycle of mESC, termed ESC-specific cell cycle regulatory miRNA 
(ESCC miRNA) (Wang et al., 2008b). These ESCC miRNA promote G1 to S transition in 
mESC by repressing expression of various cyclin E-Cdk2 inhibitors (Wang et al., 2008b). In a 
follow-up study, the same group demonstrated that ESCC miRNA, in particular mir-291-3p, 
mir-294 and mir-295, are able to enhance reprogramming efficiency when used in 
combination with Oct4, Sox2 and Klf4. These ESCC miRNA are found to be downstream 
effectors of c-Myc, and thus are able to act as substitutes for c-Myc albeit to a lesser extent 
(Judson et al., 2009). Another set of ESCC miRNA, the mir-302 cluster, is able to reprogram 
human melanoma and prostate cancer cells to ESC-like cells in the absence of any other 
reprogramming factors (Lin et al., 2008). However, it remains unclear whether miRNA on 
their own can reprogram normal human primary cells to obtain genuine iPSC, as the 
effectiveness of miRNA-based reprogramming strategies may be cell-type dependent. 
Alternatively, others have shown that suppression of pro-differentiation let-7 miRNA can 
also enhance reprogramming efficiency in mouse fibroblasts when used in combination with 
the Yamanaka factors (Melton et al., 2010). This result is consistent with the previous 
identification of Lin28 as a reprogramming factor for iPSC generation, which presumably 
acts by blocking the processing of the let-7 family of miRNA (see discussion above). 
Together, these results demonstrate opposing roles played by different miRNA in somatic 
cell reprogramming and identify miRNA as important regulators of cell pluripotency. 
Future research to screen for reprogramming effects of other miRNA members will prove 
helpful in deriving a more efficient somatic cell reprogramming method. For instance, a 
recent report showed that miRNA-145 can regulate expression of Oct4, Sox2 and Klf4 and 
represses pluripotency in hESC (Xu et al., 2009b). Therefore, it will be interesting to see 
whether miRNA-145 can contribute to somatic cell reprogramming. 
2.10 SV40 LT antigen and hTERT 
The SV40LT antigen and the catalytic subunit of hTERT are well documented for their roles 
in establishing immortalized cells. Overexpression of SV40LT and hTERT along with 
another oncogene Ras are sufficient to confer tumorigenic transformation of normal human 
cells (Hahn et al., 1999). One proposed mechanism by which SV40 functions in 
tumorigenesis is by perturbing cellular senescence pathways through suppression of p53 
activity. As discussed below, reduced p53 activity during reprogramming has been shown 
to improve the efficiency. On the other hand, reduction in telomere length during the 
normal aging process results in replicative senescence and limits the cellular lifespan of 
human cells. Studies have shown that this can be prevented by ectopic expression of hTERT 
to drive cellular immortalization (Bodnar et al., 1998). High telomerase activity is observed 
in the vast majority of tumors and is vital for the progression of malignant tumor cells (Kim 
et al., 1994). Interestingly, a previous study has also shown that c-Myc overexpression can 
activate hTERT activity (Wu et al., 1999). Therefore, SV40LT and hTERT may be able to 
contribute to somatic cell reprogramming by activating a cell cycle program that is required 
for pluripotent cells, much like the role of c-Myc in induced pluripotency.  
Two recent studies sought to enhance the efficiency of generating human iPSC by 
supplementing reprogramming factors with hTERT and/or SV40LT (Mali et al., 2008; Park 
et al., 2008). In the study by Mali et al. (2008), the reprogramming cocktails were 
supplemented with the SV40LT transgene and resulted in accelerated reprogramming 
kinetics and up to a 70-fold increase in reprogramming efficiency, depending on the 
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combination of reprogramming factors used (Mali et al., 2008). Similar results were obtained 
by Park et al. (2008) when hTERT and SV40LT were included in their reprogramming 
strategy (Park et al., 2008). Interestingly, while the addition of both SV40LT and hTERT was 
reported to increase cell proliferation, there were no viral integrations of either transgene in 
the genomes of the iPSC derived by this method (Park et al., 2008). This suggests that 
SV40LT and hTERT might be acting indirectly on supportive cells to enhance 
reprogramming. However, concerns remain about the safety of using SV40LT and hTERT in 
somatic cell reprogramming for clinical purposes. In this regard, future research studying 
whether iPSC generated using these two factors are more tumorigenic will help address this 
issue. 
2.11 Silencing of the p53/p21/p16 pathway 
One of the major roadblocks in iPSC generation is overcoming cellular senescence. p53 is 
known as the guardian of the genome and deregulation of p53 function promotes cell 
immortalization and bypasses cell senescence (Bond et al., 1994). Recent discoveries 
suggested that high-passage somatic cells with short telomeres show a dramatic decrease in 
the efficiency for iPSC generation (Marion et al., 2009; Utikal et al., 2009b). In this regard, 
bypassing cellular senescence may help improve the reprogramming efficiency of iPSC 
generation.  
Key studies have shown that knockdown of senescence factors like p53, p21CIP1 or p16INK4a 
enhances the efficiency of generating iPSC (Banito et al., 2009; Hanna et al., 2009; Hong et al., 
2009; Kawamura et al., 2009; Marion et al., 2009). Furthermore, p53 knockdown can be used 
to replace c-Myc and/or Klf4 in the Yamanaka factors (Hong et al., 2009; Kawamura et al., 
2009). When used in combination with UTF1, a chromatin bound factor highly expressed in 
pluripotent stem cells, the addition of p53  further enhanced reprogramming efficiency by 
100-fold when used with the Yamanaka factors (Zhao et al., 2008). Together these studies 
show that the p53 pathway not only acts as a roadblock for cancer but also for iPSC 
generation. As p53 is a major tumor suppressor, further studies will be required to evaluate 
the safety of p53 knockdown in iPSC generation before these iPSC can be used in clinical 
applications.  
2.12 Small molecules used to enhance somatic cell reprogramming 
It is becoming clear that reversion of somatic cells to a pluripotent state involves epigenetic 
changes to chromatin that allow different sets of genes to be expressed (Feng et al., 2009b). 
Several reports have investigated the use of small molecules to enhance current cellular 
reprogramming methods towards developing a completely transgene-free strategy. 
Huangfu et al. (2008) discovered that the addition of valproic acid (VPA), a histone 
deacetylase (HDAC) inhibitor, can increase the efficiency and kinetics of reprogramming 
(Huangfu et al., 2008a). Moreover, two other HDAC inhibitors, suberoylanilide hydroxamic 
acid (SAHA) and trichostatin A (TSA), can also improve the reprogramming efficiency, 
albeit to a lesser extent. This provides supporting evidence for the notion that chromatin 
modifiers can help to overcome the epigenetic barrier to achieving complete 
reprogramming. Furthermore, addition of VPA was also able to substitute for c-Myc and 
Klf4 during reprogramming, thus reducing the number of reprogramming factors required 
to derive iPSC (Huangfu et al., 2008b). Similar effects on enhancing reprogramming 
efficiency were also observed with DNA methyltransferase inhibitors, including azacytidine 
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(AZA) (Huangfu et al., 2008a) and RG108 (Shi et al., 2008a), as well as a histone 
methyltransferase inhibitor, BIX-01294 (Shi et al., 2008b). In addition, a calcium channel 
agonist, BayK864, was shown to enhance the effect of BIX-01294 and further improve the 
efficiency of reprogramming (Shi et al., 2008a). However, it remains unclear whether or not 
the enhancing effect of these small molecules is dependent on the cell type used for iPSC 
generation. Altogether, it is thought that histone deacetylase inhibitors (VPA, TSA, SAHA), 
methyltransferase inhibitors (AZA, RG108, BIX-01294) and possibly other, yet to be 
identified, chromatin modifiers may function by relaxing chromatin to allow ectopically 
expressed transcription factors to bind. 
Other researchers have screened small molecule libraries to identify chemical compounds 
that can directly substitute for the known reprogramming factors. This led to the discovery 
of RepSox (replacement of Sox2), a small molecule used to substitute for Sox2 in the 
reprogramming strategy (Ichida et al., 2009). RepSox acts by inhibiting transforming growth 
factor-ß (TGF-ß) signaling, in turn increasing Nanog expression that ultimately promotes 
partially reprogrammed cells to become fully reprogrammed (Ichida et al., 2009). However, 
future research will need to address the specificity of RepSox in order to fulfill its potential 
in generating iPSC for clinical purposes.  
Finally, an interesting study by Esteban et al. (2010) demonstrated that antioxidants, in 
particular vitamin C, also help to enhance somatic cell reprogramming when used in 
combination with Oct4, Sox2 and Klf4 (Esteban et al., 2010). During early stages of 
reprogramming, vitamin C is able to overcome, at least partially, the cellular senescence 
roadblock by down-regulating p53 to allow the conversion of partially reprogrammed cells 
into fully reprogrammed iPSC (Esteban et al., 2010). This study provides a natural alternative 
to synthesized small molecules and may be easier to obtain approval for clinical usage.  
3. Techniques for delivery of reprogramming factors 
Since the seminal iPSC work by Shinya Yamanaka and colleagues, the field has moved 
forward at a rapid pace. Significant progress has been made in identifying new strategies to 
enhance the reprogramming efficiency and new methods to improve clinical safety. In this 
section, we will discuss the current techniques employed to introduce the reprogramming 
factors required for iPSC generation. It is important to note that the reprogramming 
efficiencies discussed in this section are only subject to the context described in the 
particular studies. Actual efficiency can be highly affected by many factors including the cell 
type of origin, the reprogramming factors and enhancer molecules used, as well as the 
methods to calculate reprogramming efficiencies.  
3.1 Integrating Viral Vectors 
3.1.1 Retroviral vectors 
Retroviruses are efficient gene delivery vectors widely used in a broad range of dividing cell 
types. They can integrate into the host cell genome to produce continuous transgene 
expression. However, slow dividing or non-dividing cells are extremely resistant to 
retroviral transduction and the random sites of transgene integration can lead to 
unpredicatable genetic mutations within the genome and aberrant transgene expression. 
The initial derivation of iPSC utilized retroviral-mediated introduction of Oct4, Sox2, Klf4 
and c-Myc to convert mouse fibroblasts back to a pluripotent state (Takahashi and 
Yamanaka, 2006), and subsequently human iPSC derived from adult dermal fibroblasts, 
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fetal and neonatal cells (Lowry et al., 2008; Park et al., 2008; Takahashi et al., 2007). Also, it 
was observed that retroviral mediated expression of transgenes were silenced during the 
iPSC reprogramming process (Hotta and Ellis, 2008). Even with a low efficiency (0.001%-
0.5%), these pioneering studies revealed a potential alternative to the controversial use of 
ESC as a cell source for cellular transplantation therapies.  
3.1.2 Lentiviral vectors 
At the same time Yamanaka and colleagues reported the generation of human iPSC by 
retroviral transduction, Yu et al. (2007) demonstrated successful derivation of human iPSC 
using lentiviral methods to deliver a different set of factors Oct4, Sox2, Nanog and Lin28 (Yu 
et al., 2007). Lentiviruses, a subclass of retroviruses, offer the capability of high-efficiency 
infection in both dividing and non-dividing cells with stable expression of the transgenes 
and low immunogenicity. These distinguishing characteristics allow lentiviral vectors to be 
used for reprogramming a broader range of somatic cell types. However, lentiviruses 
integrate randomly into the host genome, similar to other retroviruses, which may hinder 
the use of iPSC generated using these methods for clinical applications. Initial derivation of 
human iPSC using lentiviral transduction yielded reprogramming efficiencies of 0.01%, 
significantly lower than previous retroviral methods (Yu et al., 2007). Subsequent 
improvements have been made by using lentiviral vectors to deliver SV40T, UTF1 or p53 
shRNA to supplement the reprogramming cocktails, resulting in a 70-100 fold increase in 
reprogramming efficiency (Mali et al., 2008; Zhao et al., 2008). Moreover, reporter and 
antibiotic selection casettes have also been incorporated into lentiviral vectors to aid in the 
isolation of iPSC (Hotta et al., 2009a; Hotta et al., 2009b).  
Previous studies indicated that transient expression of reprogramming factors is sufficient to 
activate the endogenous pluripotent gene program to allow for direct cell reprogramming 
(Takahashi et al., 2007; Takahashi and Yamanaka, 2006). This led to the development of 
inducible lentiviral vectors for direct cell reprogramming. Inducible lentiviral methods 
provide for improved temporal control over the levels of reprogramming factor expression 
and have been used to study the timing of reprogramming as well as the molecular changes 
that occur during the process. This system relies on inclusion of an additional vector that 
constitutively expresses the reverse tetracycline transactivator (rtTA). In the presence of the 
drug doxycycline, the rtTA functions to drive expression of the reprogramming factors, 
while in the absence of doxycycline the reprogramming transgenes are not expressed. 
Utilizing this type of inducible system, it has been established that exogenous transgene 
expression is necessary for 8-12 days to induce reprogramming of mouse fibroblasts and 
dispensable thereafter (Brambrink et al., 2008; Maherali et al., 2008; Stadtfeld et al., 2008a). 
Moreover, when doxycycline was removed eight days after initial transduction, the partially 
reprogrammed cells were unable to survive in the ESC growth conditions due to incomplete 
reactivation of their self-renewal programs. This provides a useful system to select for cells 
that have completely reverted back to a pluripotent stem cell state.  
A major obstacle encountered when attempting to transduce cells with multiple viruses is 
that only a small proportion of the total cells will become infected with all the viruses. 
During reprogramming of somatic cells, those cells infected with few viruses may fail to 
become reprogrammed; leading to a low reprogramming efficiency. In this regard, 
development of a system to express the transgenes from a single vector may substantially 
improve the efficiency. One method to express the four transgenes from a single promoter is 
to insert the self-cleaving 2A and 2A-like sequences between each cDNA sequence 
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(Donnelly et al., 1997). These 2A sequences act by triggering ribosomal skipping that result 
in expression of each sequence in a stoichiometric fashion. Importantly, efficient 
polycistronic expression by 2A-mediated separation of transgenes was achieved in hESC 
(Hasegawa et al., 2007). This strategy was recently applied to derive mouse and human iPSC 
using a single lentiviral vector expressing Oct4, Sox2, Klf4, and c-Myc (Carey et al., 2009; 
Shao et al., 2009; Sommer et al., 2009). One of the advantages of using polycistronic vectors 
is that it reduces the difficulty of handling multiple lentiviral vectors for different 
reprogramming factors. Moreover, the mouse and human iPSC generated using this method 
had less viral integration sites compared to those developed using lentiviral delivery with 
individual gene. Indeed, the results showed as few as a single viral integration was 
sufficient for reprogramming (Carey et al., 2009; Shao et al., 2009). Minimizing the number 
of viral integrations reduces the risk of tumorigenesis and genomic instability. Also, the use 
of polycistronic vectors ensures expression of all four factors in the transduced cells. 
However, reprogramming efficiencies using this method were significantly lower (0.05%) 
than previous methods and reprogramming kinetics were also notably slower. One possible 
explanation for this low reprogramming efficiency is that the reprogramming factors are 
required to be expressed at an optimal stoichiometry in order to achieve efficient direct cell 
reprogramming (Papapetrou et al., 2009). Further studies are needed to clarify if the use of 
polycistronic vectors is an ideal technique to generate iPSC.  
3.2 Non-integrating and excisable approaches 
A major concern with employing retroviral or lentiviral-based methods to derive iPSC is 
random, uncontrollable integrations of the foreign transgenes into the host chromosomes. 
While many of these integrations prove harmless to the cells, residual viral portions have 
been shown to contribute to tumor formation. Moreover, it has been suggested that viral 
integrations may be a possible cause for some of the gene expression and differentiation 
potential differences observed between blastocyst-derived ESC and iPSC. These differences 
could affect the interpretation of results during mechanistic studies and, due to the safety 
concerns, severely limit the clinical applicability of these genetically modified cells. The 
previous approaches were extremely inefficient processes and most required multiple 
integration sites to induce reprogramming. Therefore, many groups have focused on 
developing novel, non-integrating methods for deriving iPSC. Some of these methods 
include the use of non-integrating vectors, excisable vectors, as well as RNA- or protein-
based reprogramming. 
3.2.1 Adenoviral vectors 
The use of adenoviral vectors is advantageous for somatic cell reprogramming as they lack 
the machinery to integrate into the host’s genome. This allows for high-level expression of 
exogenous genes with a low risk of integration of viral transgenes into the host genome. The 
viral titer becomes diluted after every cell division, which allows transient expression of the 
transgenes. On the other hand, multiple rounds of infections can achieve prolonged 
expression of transgenes, but it can be difficult to control gene expression levels. 
Reprogramming somatic cells with adenoviral vectors was first reported by Stadtfeld et al 
(Stadtfeld et al., 2008b). Using adenoviral vectors, mouse and human iPSC were generated 
using the Yamanaka factors in various donor cell types, albeit with a low reprogramming 
efficiency as compared to integrating viral vectors (0.0001%-0.001%) (Stadtfeld et al., 2008b; 
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Zhou and Freed, 2009). Similarly, a low reprogramming efficiency was also observed using 
polycistronic adenoviral vectors (Okita et al., 2008). One explanation for this is that it is 
difficult to maintain high enough transgene levels for multiple days to allow for 
reprogramming in many of the cells. Also, roughly 20% of the transduced cells were 
tetraploid, a phenomenon which was not seen in retroviral or lentiviral induced iPSC 
(Stadtfeld et al., 2008b). The reason for this observed tetraploidy is not clear, but it was 
suggested that cellular fusion or the presence of a rare aneuploid cell population in the 
starting culture may account for this result. Therefore, further research is needed to refine 
the use of adenoviral vectors in reprogramming somatic cells back to pluripotency.  
3.2.2 Plasmids 
Another non-integrating approach to transiently express reprogramming factors is the use 
of conventional plasmids. Previous reports have successfully generated integration-free 
mouse iPSC using polycistronic plasmids to express the Yamanaka factors (Gonzalez et al., 
2009; Okita et al., 2008). However, a substantial amount of iPSC colonies contained 
integration of the transgenes. Therefore, screening of transgene integration sites is still 
necessary for iPSC generated using this technique to ensure their safety for clinical 
purposes. Furthermore, multiple rounds of transfection are required to sustain transgene 
expression at the level required to induce reprogramming and the observed reprogramming 
efficiency remained significantly lower than seen with the retroviral vectors (Gonzalez et al., 
2009; Okita et al., 2008). Improvements to this plasmid-based method were made by the use 
of a polycistronic nonviral minicircle plasmid to reprogram human adult adipose stem cells 
(Jia et al., 2010). Minicircle DNA offers a higher transfection rate and is diluted at a slower 
rate than conventional plasmids when the cells divide. As a result, fewer rounds of 
transfections are required to generate iPSC. Using this method, Jia et al. (2010) generated 
integration-free human iPSC with a reprogramming efficiency of 0.005%, an efficiency still 
much lower than the integrating viral methods (Jia et al., 2010).  
Episomal plasmids are another non-integrating method used to reprogram somatic cells into 
iPSC. Unlike conventional plasmids where transient transgene expression is gradually 
depleted after each cell division, episomal plasmids can be stably established in a number of 
cell types by drug selection and removed when the drug selection is withdrawn. Using this 
technique, Yu et al. (2009) generated a polycistronic episomal vector to co-express seven 
transgenes to reprogram human foreskin fibroblasts into iPSC (Yu et al., 2009). It was 
observed that different positioning of the transgene in the polycistronic vector resulted in 
varying reprogramming efficiencies, with the highest efficiency achieved being 0.006%. In 
summary, these studies provide proof-of-principle of the derivation of human iPSC free of 
genomic integration. However, all plasmid-based methods used to date yield a lower 
reprogramming efficiency compared to integrative viral methods, possibly due to 
difficulties in sustaining high transgene expression. Further research combining enhancing 
factors, such as small molecules, may help improve the reprogramming efficiency of these 
plasmid-based methods.  
3.2.3 Cre recombinase /loxP system 
Early non-integrating methods, such as those utilizing adenoviral and plasmid introduction 
of reprogramming factors, were substantially less efficient than the retroviral methods. 
Excisable integrating vectors offer a plausible reprogramming strategy to overcome the 
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shortcomings of both the integrating retroviral and the transient expression methods. These 
excisable systems allow high initial transgene expression followed by subsequent removal of 
exogenous factors. Soldner et al. (2009) used inducible lentiviral vectors to derive human iPSC 
from fibroblasts collected from Parkinson’s disease patients followed by Cre-recombinase 
mediated excision of the viral transgenes (Soldner et al., 2009). In this study, a constitutively 
active reverse tetracycline transactivator lentivirus was infected along with doxycycline-
inducible lentiviruses for expression of the reprogramming factors, Oct4, Sox2, Klf4 and c-
Myc. The inducible lentiviruses were engineered to contain a loxP site in the 3’ LTR that 
becomes duplicated into the 5’ LTR during viral replication, producing loxP sites flanking 
the transgenes. Subsequent expression of Cre-recombinase by electroporation allows the 
transgenes to be excised. Using this technique, the authors reported successful derivation of 
integration-free human iPSC (Soldner et al., 2009). Interestingly, the authors also 
demonstrated that the gene expression profile of these iPSC are more similar to hESC 
following transgene excision, suggesting that residual integrated reprogramming factors 
perturb the transcriptional profile of human iPSC (Soldner et al., 2009). Although the Cre-
loxP system is the most efficient recombination system known, screening of integration-free 
iPSC clones is still required, as the authors reported that only sixteen out of 180 clones 
analyzed were integration-free following excision of transgene. Moreover, Cre-mediated 
excision of the transgenes does not remove the loxP sites, which raises concern of the 
possibility of disruption of endogenous gene expression. In this regard, a recent report by 
Chang et al. (2009) demonstrated successful generation of integration-free human iPSC 
where residual loxP sites did not interrupt expression of any genes or other functional 
sequences (Chang et al., 2009).  
3.2.4 piggyBac transposon-based system  
Unlike the Cre-loxP system, the advantage of transposon-based system is that transposases can 
remove all exogenous transposon elements from the host DNA. In particular, the piggyBac 
transposons have been demonstrated to be an efficient system for excisable gene delivery, 
delivering up to 10kb DNA fragments (Ding et al., 2005). Following transfection of the 
piggyBac transposons, transient expression of the transposase enzyme catalyzes the insertion 
or the excision event (Fraser et al., 1996). The advantage of the piggyBac transposon system is 
that it can be completely removed from the host genomes without altering the DNA sequences 
at the integration sites (Wang et al., 2008a). This led to the development of piggyBac-based 
reprogramming strategy that allowed generation of mouse and human iPSC using 
tetracycline-inducible or polycistronic expression of reprogramming factors (Kaji et al., 2009; 
Woltjen et al., 2009; Yusa et al., 2009). A high reprogramming efficiency of 2.5% was reported 
in the generation of mouse iPSC using this technique (Kaji et al., 2009). Furthermore, the 
integration sites were sequenced to confirm that excision of transgenes did not alter the host 
genome. Therefore, the piggyBac transposon system represents an efficient non-integrative 
approach to generate iPSC. However, excision of the transgenes by the transposase may still 
lead to micro-deletions of the genomic DNA (Wang et al., 2008a), which could hinder the 
clinical application of iPSC generated using this method.  
3.2.5 RNA and protein-based reprogramming  
Since all of the reprogramming strategies highlighted above create the risk of unexpected 
genetic modifications, many groups have begun to devise ways to reprogram somatic cells 
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in the absence of genetic modification. Yakubov et al. (2010) recently developed a 
reprogramming technique by transfecting RNA synthesized in vitro from cDNA of Oct4, 
Lin28, Sox2, and Nanog to generate iPSC from human fibroblasts (Yakubov et al., 2010). This 
method harnesses the power of the endogenous translational machinery for proper protein 
folding and post-translational modifications. Also, this method of generating iPSC 
eliminates the risks associated with the use of viruses and DNA transfection methods. 
However, at least five consecutive transfections were necessary to reprogram these human 
fibroblasts as the transfected RNAs have a limited half-life. Finally, the reprogramming 
efficiency (0.05%) remained lower than those observed for integrating viral methods. 
Further characterization is also needed to confirm the pluripotency of the iPSC-like cells 
generated using this method and to prove the feasibility of RNA-based reprogramming. 
An alternate approach to somatic cell reprogramming without genetic modification is using 
protein transduction. Importantly, a previous study demonstrated that protein tagged with 
a C-terminus poly-arginine domain allows efficient protein transduction through the cell 
membrane (Matsushita et al., 2001). Using direct protein delivery of reprogramming factors, 
two groups have report successful derivation of iPSC with the Yamanaka factors (Kim et al., 
2009a; Zhou et al., 2009). Zhou et al. (2009) was the first to use recombinant reprogramming 
factors tagged with the poly-arginine domain to generate mouse iPSC. This virus-free and 
DNA-free method yielded a reprogramming efficiency of 0.006% with the use of an 
enhancer molecule VPA (Zhou et al., 2009). In addition, Kim et al. (2009) used whole cell 
extract from human embryonic kidney cells overexpressing the Yamanaka factors for the 
generation of human iPSC, yielding a reprogramming efficiency of 0.001% (Kim et al., 
2009a). Both studies generated iPSC without any genetic modification, making them suitable 
for clinical applications. This direct protein transduction method also eradicates the need to 
screen for integration-free iPSC, thus shortening the time required for generating clinical 
grade iPSC. However, the reprogramming efficiency achieved with this method is still far 
lower than those obtained with viral mediated reprogramming. Moreover, multiple rounds 
of treatment are required during the reprogramming process as the recombinant proteins 
become degraded overtime. Nevertheless, these studies proved the feasibility of protein-
based reprogramming methods and improvements to this technique could be important for 
final clinical application of iPSC.  
4. Conclusions 
The clinical potential of hESC for cell replacement therapies and for studying human 
diseases is undeniable. However, the use of these cells has been constantly burdened by 
both ethical (destruction of human embryos) and practical concerns (lack of available 
embryos, difficulties with generation of histo-compatible hESC). The conversion of somatic 
cells into pluripotent cells may overcome many of these roadblocks. Large numbers of 
embryos are no longer needed to create banks of patient-matched lines, since cells can now 
be harvested directly from each patient to create iPSC that are genetically identical and 
immune-compatible. Since the initial derivation of iPSC using the four Yamanaka factors, a 
growing list of reprogramming factors have been identified that either permit or enhance 
the reprogramming process. Moreover, researchers have begun to study other ways to 
improve the reprogramming efficiency, including the use of miRNA, small molecules, and 
several different methods to overcome barriers that prevent direct somatic cell 
reprogramming.  
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The first generation iPSC methods involved integration of viral transgenes, but the clinical 
necessity for deriving iPSC without these viral transgenes has pushed many researchers to 
develop alternative methods. The use of inducible polycistronic lentiviral vectors has 
already evolved to the utilization of excisable Cre-loxP and piggyBac expression systems, 
non-integrating plasmids, and recombinant proteins and RNA transfection as tools for 
generating iPSC. Advances in these non-viral, non-integrating methods will presumably 
continue until a method is discovered that can, with high efficiency, be used to derive 
patient-specific iPSC lines in a technically simple manner which can be adopted by many 
researchers and clinicians. In this regard, pursuing the development of protein-based and 
small molecule-based reprogramming methods may be most beneficial. However, these 
methods are still at an early stage and further improvements are needed to achieve high 
reprogramming efficiencies. Interestingly, a recent report utilized lentiviral vectors to 
deliver three transgenes and demonstrated direct conversion of mouse fibroblasts into 
neuronal like cells, bypassing the need of reprogramming back to a pluripotent state 
(Vierbuchen et al., 2010). Further research is needed to develop similar non-viral methods 
and to translate these techniques to human cells for clinical applications. Many 
methodologies used in the derivation of iPSC can be applied to study direct conversion of a 
somatic cell into another cell type of interest. However, the disadventagous of such direct 
reprogramming of a somatic cell into another lineage is that the reprogrammed cells are 
terminally differentiated and are not proliferating. Therefore, this reprogramming strategy 
is not ideal for large scale production to yield cells for the development of cell replacement 
therapies. In this regard, direct reprogramming of a somatic cell to a progenitor stage, where 
the progenitor cells remain proliferative, may prove advantageous. Recent studies also 
showed that iPSC retain an ‘epigenetic memory’ of their origins, where differentiation of 
iPSC to their tissue of origin is more efficient than other lineages (Kim et al., 2010; Polo et al., 
2010). This could be used as a strategy to derive efficient protocols for differentiating iPSC to 
a particular cell type of interest. In summary, the field of stem cell biology was radically 
altered by the derivation of iPSC. Since their generation, the field has moved forward at a 
staggering speed, in large part due to the potential of iPSC to transform modern medicine as 
well as our understanding of human development.  
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